On Monday 06/10/2024 the closing price of the AbbVie Inc share was $170.50 on BTT.
Compared to the opening price on Monday 06/10/2024 on BTT of $168.92, this is a gain of 0.93%.
AbbVie Inc's market capitalization is $299.23 B by 1.77 B shares outstanding.
Is AbbVie stock a Buy, Sell or Hold?
AbbVie stock has received a consensus rating of buy. The average rating score is and is based on 36 buy ratings, 8 hold ratings, and 2 sell ratings.What was the 52-week low for AbbVie stock?
The low in the last 52 weeks of AbbVie stock was 130.99. According to the current price, AbbVie is 130.16% away from the 52-week low.What was the 52-week high for AbbVie stock?
The high in the last 52 weeks of AbbVie stock was 182.85. According to the current price, AbbVie is 93.25% away from the 52-week high.What are analysts forecasts for AbbVie stock?
The 46 analysts offering price forecasts for AbbVie have a median target of 173.96, with a high estimate of 200.00 and a low estimate of 135.00. The median estimate represents a 98.01 difference from the last price of 170.50.AbbVie Stock Snapshot
170.13
Bid
50.00
Bid Size
170.61
Ask
57.00
Ask Size
6/10/2024
Date
6:04 PM
Time
175,946.00
Volume
170.45
Prev. Close
168.92
Open
299.23 B
Market Cap
1.77 B
Number of Shares
167.71
Day Low
170.80
Day High
170.50
130.99
52 Week Low
182.85
52 Week High
170.50
6.18
Dividend
3.64
Dividend Yield
13.95
P/E Ratio
99.90
Free Float in %
11.23
EPS 2024
4.91
Book Value per Share
12.45
Cash Flow per Share
AbbVie News More News
Historical Prices for AbbVie
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
AbbVie Analyst Data
Total Analysts: 46
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 135.00
Median: 173.96
Highest: 200.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
AbbVie Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/05/24 | HSBC | Upgraded to Buy | $185 | |||
| 05/17/24 | Cantor Fitzgerald | Maintained Buy | $200 | |||
| 04/29/24 | Barclays Capital | Maintained Buy | $187 | |||
| 04/29/24 | BMO Capital Markets | Maintained Buy | $180 | |||
| 03/27/24 | Barclays Capital | Maintained Buy | $195 | |||
| 03/22/24 | Guggenheim | Maintained Buy | $190 | |||
| 02/05/24 | BMO Capital Markets | Maintained Buy | $195 | |||
| 02/05/24 | Raymond James Financial, Inc. | Maintained Buy | $189 | |||
| 02/05/24 | Barclays Capital | Maintained Buy | $185 | |||
| 01/29/24 | William Blair | Upgraded to Buy | ||||
| 01/23/24 | Barclays Capital | Maintained Buy | $175 | |||
| 12/18/23 | HSBC | Downgraded to Sell | $156 | |||
| 12/11/23 | Goldman Sachs | Upgraded to Buy | $173 | |||
| 12/01/23 | Raymond James Financial, Inc. | Maintained Buy | $181 | |||
| 11/09/23 | Deutsche Bank | Maintained Hold | $150 | |||
| 10/30/23 | Morgan Stanley | Maintained Buy | $196 | |||
| 10/30/23 | Barclays Capital | Upgraded to Buy | $170 | |||
| 10/11/23 | Morgan Stanley | Maintained Buy | $193 | |||
| 09/29/23 | Raymond James Financial, Inc. | Maintained Buy | $177 | |||
| 07/28/23 | Piper Sandler | Maintained Buy | $170 | |||
| 07/25/23 | William Blair | Maintained Hold | ||||
| 07/14/23 | HSBC | Maintained Buy | $167 | |||
| 07/11/23 | Morgan Stanley | Maintained Buy | $182 | |||
| 04/28/23 | Guggenheim | Maintained Buy | $171 | |||
| 04/28/23 | Morgan Stanley | Maintained Buy | $182 | |||
| 04/28/23 | Wells Fargo & Co | Maintained Buy | $195 | |||
| 04/10/23 | Morgan Stanley | Maintained Buy | $181 | |||
| 04/05/23 | Argus Research Company | Downgraded to Hold | ||||
| 03/01/23 | Guggenheim | Maintained Buy | $172 | |||
| 02/22/23 | Wolfe Research | Downgraded to Hold | ||||
| 02/10/23 | SVB Leerink | Upgraded to Hold | $153 | |||
| 02/10/23 | Atlantic Equities | Maintained Hold | $154 | |||
| 02/10/23 | Morgan Stanley | Maintained Buy | $178 | |||
| 02/10/23 | Piper Sandler | Maintained Buy | $163 | |||
| 02/06/23 | BMO Capital Markets | Maintained Buy | $167 | |||
| 01/17/23 | Piper Sandler | Maintained Buy | $157 | |||
| 12/06/22 | Morgan Stanley | Maintained Buy | $182 | |||
| 11/18/22 | Credit Suisse | Maintained Buy | $170 | |||
| 10/31/22 | Atlantic Equities | Maintained Hold | $157 | |||
| 10/31/22 | Morgan Stanley | Maintained Buy | $178 | |||
| 10/31/22 | BMO Capital Markets | Maintained Buy | $169 | |||
| 10/31/22 | Barclays Capital | Maintained Hold | $155 | |||
| 10/11/22 | Morgan Stanley | Maintained Buy | $185 | |||
| 09/30/22 | SVB Leerink | Maintained Sell | $135 | |||
| 08/24/22 | Argus Research Company | Maintained Buy | $155 | |||
| 08/01/22 | UBS | Maintained Hold | $146 | |||
| 08/01/22 | Morgan Stanley | Maintained Buy | $188 | |||
| 08/01/22 | Barclays Capital | Maintained Hold | $160 | |||
| 08/01/22 | Atlantic Equities | Maintained Hold | $162 | |||
| 07/08/22 | Morgan Stanley | Maintained Buy | $191 |
AbbVie Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 55,181 | 58,244 | 62,420 | 66,408 | 70,773 |
| Dividend | 6.18 | 6.47 | 6.77 | 7.18 | 7.54 |
| Dividend Yield (in %) | 3.64 % | 3.81 % | 3.98 % | 4.22 % | 4.44 % |
| EPS | 11.23 | 12.04 | 13.38 | 14.69 | 16.13 |
| P/E Ratio | 15.13 | 14.11 | 12.70 | 11.57 | 10.53 |
| EBIT | 25,557 | 27,559 | 30,318 | 32,925 | 35,840 |
| EBITDA | 26,381 | 28,492 | 31,168 | 35,218 | 38,689 |
| Net Profit | 19,960 | 21,397 | - | 25,964 | 28,440 |
| Net Profit Adjusted | 19,960 | 21,397 | - | 25,964 | 28,440 |
| Pre-Tax Profit | 23,755 | 25,500 | - | 30,677 | 34,171 |
| Net Profit (Adjusted) | 11,624 | 14,491 | 19,463 | 24,699 | 26,347 |
| EPS (Non-GAAP) ex. SOE | 11.23 | 12.04 | 13.38 | 14.69 | 16.13 |
| EPS (GAAP) | 4.99 | 6.60 | 9.55 | 10.89 | 13.17 |
| Gross Income | 45,459 | 48,042 | 51,576 | 55,682 | 59,315 |
| Cash Flow from Investing | -16,948 | -1,467 | -1,700 | -1,276 | -1,295 |
| Cash Flow from Operations | 20,101 | 23,890 | 26,295 | 27,254 | 30,078 |
| Cash Flow from Financing | -3,267 | -15,382 | -14,771 | -14,011 | -14,445 |
| Cash Flow per Share | 12.45 | 13.59 | 13.71 | 14.18 | 17.06 |
| Free Cash Flow | 18,603 | 23,497 | 25,832 | 21,505 | - |
| Free Cash Flow per Share | 9.92 | 11.83 | 13.81 | - | - |
| Book Value per Share | 4.91 | 5.64 | 7.08 | 7.61 | 8.78 |
| Net Debt | 56,577 | 47,842 | 38,031 | 31,474 | 11,540 |
| Research & Development Exp. | 7,764 | 7,993 | 8,422 | 8,772 | 9,172 |
| Capital Expenditure | 794 | 780 | 824 | 797 | 776 |
| Selling, General & Admin. Exp. | 13,064 | 13,449 | 13,891 | 14,213 | 14,601 |
| Shareholder’s Equity | 13,429 | 18,115 | 22,893 | 36,952 | 54,222 |
| Total Assets | 144,078 | 144,548 | 150,983 | 163,408 | 184,793 |
|
Previous Quarter ending 03/31/24 |
Current Quarter ending 06/30/24 |
Next Quarter ending 09/30/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 18 | 20 | 20 | 26 | 26 |
| Average Estimate | 2.260 USD | 3.052 USD | 2.908 USD | 11.233 USD | 12.044 USD |
| Year Ago | 2.460 USD | 2.910 USD | 2.950 USD | 11.110 USD | 11.233 USD |
| Publish Date | 4/26/2024 | 7/26/2024 | 10/25/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 16 | 18 | 18 | 25 | 25 |
| Average Estimate | 11,930 USD | 14,010 USD | 14,167 USD | 55,181 USD | 58,244 USD |
| Year Ago | 12,225 USD | 13,865 USD | 13,927 USD | 54,318 USD | 55,181 USD |
| Publish Date | 4/26/2024 | 7/26/2024 | 10/25/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales | 28,216 | 32,753 | 33,266 | 45,804 | 56,197 | 58,054 | 54,318 |
| Change of sales in % | 10.06 | 16.08 | 1.57 | 37.69 | 22.69 | 3.30 | -6.44 |
| Gross profit on sales | 21,412 | 25,196 | 25,660 | 31,686 | 39,053 | 41,609 | 37,668 |
| Gross profit on sales change in % | 8.01 | 17.67 | 1.84 | 23.48 | 23.25 | 6.54 | -9.47 |
| Operating income | 10,611 | 12,138 | 13,915 | 15,630 | 19,749 | 22,602 | 18,082 |
| Operating income change in % | 8.33 | 14.39 | 14.64 | 12.32 | 26.35 | 14.45 | -20.00 |
| Income before tax | 7,727 | 5,197 | 8,426 | 3,398 | 12,989 | 13,477 | 6,250 |
| Income before tax change in % | -1.99 | -32.74 | 62.13 | -59.67 | 282.25 | 3.76 | -53.62 |
| Income after tax | 5,283 | 5,657 | 7,842 | 4,556 | 11,468 | 11,782 | 4,820 |
| Income after tax change in % | -10.81 | 7.08 | 38.62 | -41.90 | 151.71 | 2.74 | -59.09 |
Balance Sheet
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 65,689 | 67,798 | 97,287 | 137,468 | 131,093 | 121,518 | 124,314 |
| Total liabilities change in % | 30.81 | 34.19 | 55.24 | 61.64 | 54.23 | 51.99 | 48.97 |
| Equity | 5,097 | -8,446 | -8,172 | 13,097 | 15,436 | 17,287 | 10,397 |
| Equity change in % | 9.94 | -265.71 | 3.24 | - | 17.83 | 11.98 | -39.96 |
| Balance sheet total | 70,786 | 59,352 | 89,115 | 150,565 | 146,529 | 138,805 | 134,711 |
| Balance sheet total change in % | 7.09 | -16.15 | 50.15 | 68.96 | -2.68 | -5.27 | -2.95 |
Key Data
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 17.60 | 21.19 | 22.42 | 27.38 | 31.62 | 32.65 | 30.64 |
| P/E ratio (year end quote, basic EPS) | 29.31 | 25.19 | 16.75 | 39.35 | 20.98 | 24.39 | 57.00 |
| P/E ratio (ear end quote, diluted EPS) | 29.31 | 25.19 | 16.75 | 39.35 | 20.98 | 24.39 | 57.00 |
| P/E ratio (year end quote) | 29.31 | 25.19 | 16.75 | 39.35 | 20.98 | 24.39 | 57.00 |
| Dividend yield in % | 2.72 | 4.28 | 4.96 | 4.52 | 3.92 | 3.53 | 3.87 |
| Equity ratio in % | 7.20 | -14.23 | -9.17 | 8.68 | 10.52 | 12.43 | 7.69 |
| Debt ratio in % | 92.80 | 114.23 | 109.17 | 91.30 | 89.47 | 87.55 | 92.28 |
AbbVie Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| TILTON GLENN F | 05/02/2024 | 1,322.00 | 50,361.00 | n/a | Buy | No |
| Davis Jennifer L. | 05/02/2024 | 1,322.00 | 1,322.00 | n/a | Buy | No |
| Donoghoe Nicholas | 03/19/2024 | 21,082.00 | 55,903.00 | 176.30 | Sell | No |
| Stewart Jeffrey Ryan | 03/17/2024 | 5,099.00 | 88,681.00 | 179.03 | Sell | No |
| Stewart Jeffrey Ryan | 03/17/2024 | 27,740.00 | 60,941.00 | 178.69 | Sell | No |
| Stewart Jeffrey Ryan | 03/17/2024 | 26,110.00 | 93,780.00 | 178.85 | Sell | No |
| Stewart Jeffrey Ryan | 03/17/2024 | 26,110.00 | 119,890.00 | 61.36 | Buy | No |
| RICHMOND TIMOTHY J. | 02/29/2024 | 30,288.00 | 43,817.00 | 177.71 | Sell | No |
| RICHMOND TIMOTHY J. | 02/29/2024 | 15,412.00 | 74,105.00 | 176.40 | Sell | No |
| RICHMOND TIMOTHY J. | 02/29/2024 | 9,853.00 | 33,964.00 | 176.35 | Sell | No |
| RICHMOND TIMOTHY J. | 02/29/2024 | 20,127.00 | 13,837.00 | 177.71 | Sell | No |
| RICHMOND TIMOTHY J. | 02/29/2024 | 45,700.00 | 89,517.00 | 61.36 | Buy | No |
| Buckbee Kevin K | 02/28/2024 | 5,144.00 | 6,983.00 | 176.65 | Sell | No |
| Siatis Perry C | 02/28/2024 | 6,504.00 | 13,784.00 | 177.05 | Sell | No |
| Siatis Perry C | 02/28/2024 | 3,387.00 | 10,397.00 | 178.04 | Sell | No |
| Michael Robert A. | 02/28/2024 | 21,560.00 | 145,964.00 | 176.44 | Sell | No |
| Michael Robert A. | 02/28/2024 | 47,319.00 | 98,645.00 | 176.46 | Sell | No |
| Michael Robert A. | 02/28/2024 | 11,420.00 | 157,384.00 | 61.36 | Buy | No |
| Michael Robert A. | 02/28/2024 | 10,140.00 | 167,524.00 | 54.86 | Buy | No |
| Reents Scott T | 02/27/2024 | 11,634.00 | 15,431.00 | 178.99 | Sell | No |
| Buckbee Kevin K | 02/27/2024 | 5,339.00 | 13,872.00 | 178.99 | Sell | No |
| GONZALEZ RICHARD A | 02/27/2024 | 138,616.00 | 519,099.00 | 177.27 | Sell | No |
| GONZALEZ RICHARD A | 02/27/2024 | 110,249.00 | 657,715.00 | 178.99 | Sell | No |
| RICHMOND TIMOTHY J. | 02/27/2024 | 23,847.00 | 43,817.00 | 178.99 | Sell | No |
| Hudson Thomas J | 02/27/2024 | 20,634.00 | 107,267.00 | 178.99 | Sell | No |
AbbVie Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | AbbVie Inc | 5.99 | 3.87 | USD |
| 2022 | AbbVie Inc | 5.71 | 3.53 | USD |
| 2021 | AbbVie Inc | 5.31 | 3.92 | USD |
| 2020 | AbbVie Inc | 4.84 | 4.52 | USD |
| 2019 | AbbVie Inc | 4.39 | 4.96 | USD |
| 2018 | AbbVie Inc | 3.95 | 4.28 | USD |
| 2017 | AbbVie Inc | 2.63 | 2.72 | USD |
| 2016 | AbbVie Inc | 2.35 | 3.75 | USD |
| 2015 | AbbVie Inc | 2.10 | 3.54 | USD |
| 2014 | AbbVie Inc | 1.75 | 2.67 | USD |
| 2013 | AbbVie Inc | 1.60 | 3.03 | USD |
| 2012 | AbbVie Inc | 0.40 | 1.17 | USD |
| 2011 | AbbVie Inc | USD | ||
| 2010 | AbbVie Inc | USD | ||
| 2009 | AbbVie Inc | USD |
*Yield of the Respective Date
AbbVie Inc Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 3.052 USD | Q2 2024 Earnings Release | 07/26/2024 |
| Earnings Report | 2.908 USD | Q3 2024 Earnings Release | 10/25/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 01/29/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 04/25/2025 |
AbbVie Inc Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/03/2024 |
| Press Conference | - | - | 04/26/2024 |
| Earnings Report | 2.310 USD | Q1 2024 Earnings Release | 04/26/2024 |
| Press Conference | - | - | 02/02/2024 |
AbbVie Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Moody’s Daily Credit Risk Score
AbbVie Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.90 |
| Vanguard Group, Inc. (Subfiler) | 9.17 |
| The Vanguard Group, Inc. | 9.06 |
| State Street Corp. | 4.40 |
| Vanguard Total Stock Market ETF | 3.14 |
| BlackRock Fund Advisors | 3.03 |
| Capital Research & Management Co. (International Investors) | 2.72 |
| Vanguard 500 Index Fund | 2.54 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 2.12 |
| JPMorgan Investment Management, Inc. | 1.79 |
| Capital Research & Management Co. (Global Investors) | 1.77 |
| Charles Schwab Investment Management, Inc. | 1.28 |
| Fidelity 500 Index Fund | 1.21 |
| Norges Bank (13F) | 1.18 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
AbbVie Management
| Name | Job |
|---|---|
| Richard A. Gonzalez | Chairman & Chief Executive Officer |
| Nicholas Donoghoe | Chief Business & Strategy Officer |
| Scott T. Reents | Chief Financial Officer & Executive Vice President |
| Timothy J. Richmond | Chief Human Resources Officer & Executive VP |
| Roopal Thakkar | Chief Medical Officer & SVP |
| Thomas J. Hudson | Chief Scientific Officer, Senior VP-R&D |
| Azita Saleki-Gerhardt | Co-Chief Operations Officer & Executive VP |
| Liz Shea | Head-Investor Relations |
| Jennifer L. Davis | Independent Director |
| Frederick H. Waddell | Independent Director |
| William H. L. Burnside | Independent Director |
| Rebecca Brown Roberts | Independent Director |
| Roxanne Schuh Austin | Independent Director |
| Susan E. Quaggin | Independent Director |
| Brett J. Hart | Independent Director |
| Thomas C. Freyman | Independent Director |
| Edward J. Rapp | Independent Director |
| Robert J. Alpern | Independent Director |
| Melody B. Meyer | Independent Non-Executive Director |
| Glenn Fletcher Tilton | Lead Independent Director |
| Robert A. Michael | President & Chief Operating Officer |
| Perry C. Siatis | Secretary, Executive VP & General Counsel |
| Carrie Strom | Senior VP & President-Global Allergan Aesthetics |
| Kevin K. Buckbee | Senior Vice President & Controller |
| Brian L. Durkin | Vice President |
| Todd D. Bosse | Vice President-Investor Relations |
| Esteban Plata | Vice President-Western Europe & Canada |